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Boronic acids are a promising class of compounds due to their wide range of 
applications in medicinal and materials chemistry, and as coupling agents in organic 
synthesis. B-hydroxy-1,2-oxaborolanes (benzoboroxoles) are categorized as cyclic 
boronic acid derivatives and they are very important organic molecules because of their 
metabolic stability and their ability to undergo important C-C bond forming reactions 
such as Suzuki cross coupling. Several of these cyclic boronic acids are found to have 
promising pharmacological properties as antifungal, antimalarial and anti-inflammatory 
agents. However, based on the literature reports, synthesis of highly functionalized 
benzoboroxoles is typically cumbersome and not very conducive for large-scale 
synthesis.  
This thesis details our efforts on the development of novel synthetic 
methodologies for the synthesis of functionalized benzoboroxoles as potential therapeutic 
agents. We initiated the synthesis of novel benzoboroxoles starting from 2-
formylphenylboronic acid employing reactions such as Baylis-Hillman reaction, Passerini 
reaction, aldol reaction, and reductive amination.  Further functionalization of these 
benzoboroxoles was achieved via nitrosation and amidation protocols.  The biological 
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   Organoboron compounds in general and boronic acids in particular have been 
underutilized in medicinal chemistry, as there is a misconception among the scientific 
community that the boron compounds are in general toxic.  Owing to their impressive 
chemical and biological profile, boronic acids and boronate esters have been utilized as 
valuable synthons for cross-coupling1, homologation2, aldol, and catalytic allylboration3 
reactions to name a few. Boronic acids also find utility in medicinal chemistry as 
chemotherapeutic4 and radiotherapeutic (BNCT) agents5.  
Aminoboronic Acids 
 Aminoboronic acids 1 are ideal bioisosteric replacements for amino acids 2 owing 
to their comparable stereoelectronic properties and hence they find several applications in 
peptidomimetics6.  Boronic acid is a six electron species, hence it is a strong electrophile 
and forms a stable “ate” complex 3 when it interacts with nucleophiles such as hydroxyl 
termini of enzymes.  Carboxylic acids produce an unstable tetrahedral carbonyl addition 
intermediate 4 under similar conditions (Figure 1).  The stable bond formation between 
boronic acids and enzymes leads to their reversible inhibition, accordingly the former 
acts as an excellent pharmacophore in pharmaceutical chemistry.  This mechanism of 
action resulted in the FDA approval for bortezomib 5 (Velcade®, Figure 2) as an anti-
cancer drug for the treatment of multiple myeloma7.  This event marked a new beginning 
into the use of organoboron compounds for drug discovery.  Buoyed by the success of 
  2
bortezomib, large-scale biological screening of boronated compounds was carried out and 
based on these studies, a second-generation drug ixazomib 6 (Ninlaro®) was also 
approved recently by the FDA for the treatment of multiple myeloma8. Ixazomib citrate 
7, is an orally bioavailable prodrug form of ixazomib which is also used clinically as it 













Figure 2. Boronic acids in clinical use. 
Benzoboroxoles 
 Benzoboroxoles (or benzoxaboroles) 8 are one such class of cyclic boronic acid 
hemiester analogs that have found applications in medicinal, materials, and polymer 
chemistry because of their unusual chemical stability and ideal physicochemical 
properties9.  First synthesized by Torsell10 in 1957, and later explored briefly by Snyder,11 
this class of boron compounds remained dormant for several decades until the approval 
of two drugs tavaborole 912 (for the treatment of onychomycosis) and crisaborole 1013  
(for the topical treatment of atopic dermatitis) (Figure 3).  The excellent anti-fungal 
activity of tavaborole is attributable to the inhibition of Leucyl-tRNA synthetase, while 




Figure 3. Benzoboroxoles in clinical use. 
                 Owing to our long-standing interest in boron chemistry14, our group has been 
working on the functionalization of benzoboroxoles as therapeutic agents.  We 
demonstrated the utility of Baylis-Hillman reaction15 using o-boronobenzaldehyde 11 for 
the formation of functionalized benzoboroxoles 12-13 with activated olefins such as 
methyl acrylate, acrylonitrile, methyl vinyl ketone, acrolein and cyclohex-2-enone.16   
Benzoboroxole-based esters 14 were obtained via the reaction of functionalized allylic 
bromides with the aldehyde 11 under Barbier allylation conditions.16 Benzoboroxole-
based ketones and esters (15 and 16) were obtained via aldol condensation of 
boronoaldehyde 11 with acetophenone and dimethyl malonate respectively (Figure 1, 
paths d-e).17  Our group was also successful in carrying out Passerini reaction18 of 
aldehyde 11 with isonitriles to furnish the benzoboroxole amides 7 (Figure 4).19 
  5
 
Figure 4. Diverse functionalization of benzoboroxoles. 
Applications of Benzoboroxoles in Medicinal Chemistry 
  There have been several reports on the applications of benzoboroxoles in 
medicinal chemistry.  Most notable are their uses as anti-fungal agents (tavaborole)12 and 
anti-inflammatory agents (crisaborole).13  Other applications of these molecules are noted 
below. 
  Anti-Tubercular agents. Our group described a simple synthesis of 6-amino-7-
bromobenzoboroxole 20.  This analog showed promising activity against Mycobacterium 
tuberculosis H376Rv. This compound 20 was obtained in four steps via reduction of o-
formylphenylboronic acid 11 with sodium borohydride followed by electrophilic 
  6
nitration of benzoboroxole 8, reduction, and monobromination.  We were also able to 





Figure 5. Preparation of benzoboroxoles as anti-tubercular agents. 
 Benzoboroxoles 22-24 exhibited excellent activity against M. tuberculosis 






Figure 6. Benzoboroxoles in preclinical development as anti-tubercular agents. 
 Anti-Malarial agents. 6-Aryloxy-7-alkylbenzoboroxoles 25 and 26 showed 
impressive in vitro and in vivo biological activity against Plasmodium falciparum thus 
demonstrating their potential as anti-malarial agents (Figure 7)22.  
 
 





 Ectoparasiticidic agents. Isoxazoline-based benzoboroxoles 27 exhibited 




Figure 8. Benzoboroxoles in preclinical development as ectoparasiticidic agents. 
 Anti-Trypanosomiasis agents. A valine amide substituted benzoboroxole 28 
expressed activity against two protozoan parasites are primarily responsible for African 
trypanosomiasis in animals namely Trypanosoma congolense and T. vivax. 6-
Pyrrolobenzoboroxole 29 was identified as a lead candidate for human African 
trypanosomiasis or sleeping sickness (Figure 9).23 
 
 
Figure 9. Benzoboroxoles in preclinical development as anti-trypanosomiasis agents. 
 
  9
 Miscellaneous applications. A clarithromycin-benzoboroxole conjugate 30 
proved to be a more potent derivative than the parent drug clarithromycin against gram-
positive bacterial strains.24  Similarly, amphotericin benzoboroxole conjugates 31a-b 
showed very good antifungal activity against Candida albicans, Cryptococcus humicolus, 
Aspergillus niger, and Fusarium oxysoprum.25  Thiadiazolyloxy benzoboroxole 
derivative 32 is a potent inhibitor of serine -lactamase26 and 3-
aminomethylbenzoboroxole 33 is an effective inhibitor of human protozoan pathogens 






Figure 10. Miscellaneous medicinal applications of benzoboroxoles. 
 In addition to the analogs mentioned above, several other benzoboroxole 
derivatives with anti-inflammatory28, and anti-viral (HCV protease)29 activities have also 
been developed. In addition to the applications in medicinal chemistry, benzoboroxoles 
  11
and their derivatives have also been extensively utilized as hydrogels, and for 
oligosaccharide detection.30 
 Apart from boronic acids and benzoboroxoles, carboranes are another class of 
boron compounds that have attracted significant attention because of their applications as 
chemo- and radiotherapeutic agents.31 BODIPY (boron-dipyrromethene), a valuable 
fluorophore, is a family of fluorescent boron compounds that have found imaging 
applications because of their stability and higher quantum yields under physiological 
conditions.32 The other uses of boron compounds include their use as electrochemical 
sensors for recognition of anions and small molecules,33 use of boron based polymers for 
the development of thermoresponsive hydrogels, HIV barrier gels, nanoparticles and 
block copolymers for drug delivery applications.34  
  12
Chapter 2 
Reductive Amination for the Preparation of Benzoboroxoles 
 In this project, we envisioned the preparation of aromatic ring-functionalized 
benzoboroxoles while leaving the benzylic carbon unbranched on the oxaborole ring so 
as to improve the biological efficacy.  Herein, we provide an account of our synthetic and 
biological evaluation results.35 
Preparation of Aminobenzoboroxole 
 We started synthesis of precursor aminobenzoboroxole 19 in three steps starting 
from 2-formylphenylboronic acid 11. In the first step, reduction of 2-
formylphenylboronic acid 11 was carried out with NaBH4 in methanol at 0 °C to yield 
benzoboroxole 8 in 87% yield (Figure 11). The formation of boroxole ring was 
confirmed by 1H-NMR spectrum, which showed a characteristic signal at δ 4.80 (2H) 
corresponding to the benzylic methylene protons. 
 
 






 In the second step, nitration of benzoboroxole 8 was carried out with fuming nitric 
acid to afford 6-nitrobenzoboroxole 18 as white solid in 68% yield.11b,36 Further, 6-
nitrobenzoboroxole underwent reduction with zinc and hydrochloric acid to result in the 
formation of 6-aminobenzoboroxole 19 as pale yellow solid in 78% yield (Figure 12). A 
detailed 1H-NMR comparative analysis of nitrobenzoboroxole and aminobenzoboroxole 
revealed an upfield shift of C-7 proton signal from δ 8.57 (1H) to δ 7.00 (1H), thus 
confirming the formation of 6-aminobenzoboroxole. None of these compounds required 
any chromatographic purification and the compounds could be readily obtained upon 





Figure 12. Preparation of 6-aminobenzoboroxole. 
Preparation of N-Benzylaminobenzoboroxole 
 After synthesizing 6-aminobenzoboroxole 19, we attempted the reductive 
amination of benzaldehyde with 19 in methanol at room temperature, and complete 
conversion of amine to imine 34 was observed after stirring for 3 h. Sodium borohydride 
was then added to the reaction mixture at room temperature and stirred for 2 h to affect 
reduction of the imine. Our initial efforts of isolating the product 35 proved difficult and 
the standard work up with ethyl acetate and water after evaporation of ethanol did not 
  14
furnish the product N-benzylaminobenzoboroxole 35. The product was obtained after 
acidification with dilute HCl to pH 1 and work up with ethyl acetate, albeit in low yields 
(~30%). The isolation step was eventually successful after careful neutralization of the 
aqueous solution to a neutral pH, at which point, the product started precipitating out of 
the solution and N-benzylaminobenzoboroxole 35 was obtained in 82% yield.  The solid 
was then filtered and dried over vacuum to obtain analytically pure product 35 (Figure 
13). The 1H-NMR analysis revealed a signal at δ 4.26 (2H) as a doublet corresponding to 
benzylic methylene protons adjacent to the amine and a triplet at δ 6.20 (1H) 
corresponding to the secondary amine proton thus confirming the formation of N-
benzylaminobenzoboroxole 35.  
 
 
Figure 13. Preparation of N-alkylaminobenzoboroxoles via reductive amination. 
 To evaluate the efficiency of this methodology, variety of aldehydes substituted 
with electron withdrawing as well as electron donating groups were subjected to 
  15
reductive amination with 6-aminobenzoboroxole 19. All of these aldehydes readily 
reacted with 19 at room temperature and complete formation of the imine was observed 
in all these cases within 3-4 h. The imines were then subjected to NaBH4 reduction to 
afford the products 35a-m in 72-85% overall yields (Figure 14). As expected, imine 
formation was observed to be relatively faster with electron withdrawing group 
substituted aldehydes and slightly better yields of the product were observed in these 
cases (Figure 14). All the compounds 35a-m were characterized using NMR and mass 




Figure 14. Reductive amination for the preparation of aminobenzoboroxoles. 
Preparation of Aminobenzoboroxole-Flutamide Hybrid 
 Using the reductive amination strategy, an aminobenzoboroxole-flutamide hybrid 
congener 39 was also synthesized. The condensation of 4-nitro-3-trifloromethylaniline 36 
with p-formylbenzoic acid in the presence of POCl3 yielded the amido aldehyde 38 in 
72% yield. The aldehyde 38 was then subjected to reductive amination with 6-
aminobenzoboroxole 19 under standard conditions in a one-pot procedure as described 
  17





Figure 15. Preparation of aminobenzoboroxole-flutamide hybrid. 
Preparation of Chloroquinoline-Aminobenzoboroxole Conjugate 
 A chloroquinoline-aminobenzoboroxole conjugate 42 was also synthesized in a 
similar manner starting from 2-chloroquinoline carbaldehyde 41. The aldehyde 41 was 
synthesized from acetanilide 40 under Vilsmeier-Haack formylation conditions using 
POCl3 and DMF.  The condensation of aldehyde 41 with aminobenzoboroxole 19 




Figure 16. Preparation of chloroquinoline-aminobenzoboroxole conjugate.  
Preparation of N-Nitrosoaminobenzoboroxoles 
 Nitrosoamines and nitrosoureas37 are of interest for the treatment of various types 
of cancers and compounds such as lomustine and carmustine are prescribed as DNA 
alkylating drugs in chemotherapy. To demonstrate the robustness of the benzoboroxole 
moiety, some of the representative secondary amines 35 reported above were subjected to 
nitrosation.  All of the compounds readily reacted with sodium nitrite and HCl in 
acetonitrile/water solvent system and the corresponding N-nitrosoaminobenzoboroxoles 
43a-f precipitated out of the reaction within 1-2 h (Figures 17-18). The products were 
obtained in high yields and were characterized by standard analytical techniques. A 
detailed 1H-NMR comparative analysis of aminobenzoboroxole 35 and N-
nitrosoaminobenzoboroxole 43a revealed a downfield shift of benzylic methylene 
  19
protons adjacent to the amine from δ 4.26 (d, 2H) to δ 5.33 (s, 2H) as well as the 
disappearance of the secondary amine signal, thus confirming the formation of N-









Figure 18. N-nitrosoaminobenzoboroxoles. 
Preparation of Aminobenzoboroxole-Based Urea Derivatives 
   The aminobenzoboroxoles 35 were further reacted with phenyl, cyclohexyl, and 
2-chloroethyl isocyanates in dioxane to furnish the urea derivatives 44a-f in 79-84% 
yields (Figures 19-20). The pure products were obtained upon the removal of solvent and 
addition of cold water. The products were filtered, dried, and characterized by IR, NMR, 
and mass spectrometry. In the case of cyclohexyl isocyanate and 2-chloroethyl 
isocyanate, the products had to be further triturated with hexane under sonication to 













Figure 20. Aminobenzoboroxole-based urea derivatives. 
 After synthesizing the nitrosamine (43) and urea based benzoboroxoles (44), we 
attempted to extend our efforts to synthesize N-nitrosourea derivatives of 
benzoboroxoles.  However, our efforts towards the nitrosation of phenylureas 44 did not 




Figure 21. Preparation of N-nitrosourea derivatives of benzoboroxoles. 
Biological Evaluation of Aminobenzoboroxoles 
 After synthesizing the functionalized aminobenzoboroxoles, these molecules were 
evaluated for their general cytotoxicity against breast cancer cell lines (MDA-MB-231) 
and pancreatic cancer cell lines (MIAPaCa-2). While most of the compounds tested were 
not found to exhibit any significant cytotoxicity at 12.5 and 50 M concentration, couple 
of derivatives 42 and 44b showed activity against MIAPaCa-2 cell lines at 12.5 M 














       Table 1 
       Cell Viability of Aminobenzoboroxoles on Cancer Cell Lines. 
Compound structure MIAPaCa-2 MDA-MB-231 
50mM 12.5mM 50mM 12.5mM 
              35a
34.5 76.6 80.2 73.7 
           35b 
73.6 87.2 91.7 84.0 
        35c 
63.9 90.9 90.0 80.2 
        35d 
65.8 86.4 75.7 75.2 
         35e
62.6 95.3 68.7 69.2 
         35f 
37.9 51.8 90.0 90.2 
         35g 
80.6 71.3 123.6 100.1 
         
35h 
69.0 88.9 101.7 88.5 
          
35i 
47.0 80.8 109.2 77.7 
         35j 
78.4 72.1 71.1 97.6 
  25
        Table 1 (continued) 
        35k 
49.5 92.0 90.7 93.9 
     35l 
58.2 89.1 102.6 106.5 
          35m 
45.9 57.2 82.8 84.1 
   
39 
77.7 85.8 49.5 112.0 
   42
28.6 28.2 44.8 44.3 
Control 100.0 100.0 100.0 100.0 
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Table 2 
Cell Viability of N-Nitrosoaminobenzoboroxoles on Cancer Cell Lines. 
Compound structure MIAPaca MDA-MB-231 
50mM 12.5mM 50mM 12.5mM 
                43a 
51.5 83.5 115.3 120.7 
                43b 
62.8 77.7 107.9 128.3 
             43c 
70.5 70.3 125.6 121.7 
           43d 
69.5 95.7 106.1 133.7 
               43e 
59.9 84.8 146.0 121.5 
                43f 
61.0 83.0 123.2 118.7 






Cell Viability of Aminobenzoboroxole-based Ureas on Cancer Cell Lines. 
Compound structure MIAPaca MDA-MB-231 
50mM 12.5mM 50mM 12.5mM 
          44a 
30.0 49.6 47.0 115.9 
          44b 
17.5 22.4 53.9 63.0 
           
44c 
39.4 64.8 127.6 80.9 
          44d 
25.1 45.5 60.8 96.3 
         44e 
61.8 103.9 100.9 134.8 
          44f 
60.4 74.9 63.2 95.8 
Control 100.0 100.0 100.0 100.0 
  28
 The IC50 values for the two most active derivatives 42 and 44b were found to be 
11.5 M and 11.9 M respectively in human breast cancer cell lines MDA-MB-231. 
Similarly, the IC50 values for these compounds were determined to be 8.3 M and 2.7 















 We have developed a method for the preparation of 6-aminobenzoboroxoles using 
zinc/acetic acid reduction of 6-nitrobenzoboroxole.  The aminobenzoboroxoles were 
further utilized for reductive amination of a variety of aldehydes. Further, the resulting N-
alkylaminobenzoboroxoles have also been transformed into N-benzoboroxolylureas as 
well as N-nitroso-aminobenzoboroxoles. The initial cell based biological evaluation of 
these molecules has shown some promise and we have been able to identify various leads 









 2-Formylphenylboronic acid was purchased from AK Scientific, Inc. All other 
reactants were of reagent grade, purchased from Acros Organics, Alfa Aesar and Sigma 
Aldrich, and used without further purification. All solvents were used without further 
drying or purification and were of ACS grade purchased from Fisher Scientific. 
Instrumentation 
 Nuclear Magnetic Spectroscopy (NMR) NMR spectra were produced using the 
Varian 400 MHz spectrophotometer. The instrument was maintained at 25o C operating 
at 400 MHz for 1H NMR, and 100 MHz for 13C NMR. The deuterated solvent (CDCl3, 
DMSO-d6) used for each respective spectrum is referenced to the appropriate literature 
peak shift. 
Procedure for the Preparation of 6-Aminobenzoboroxole 
 6-Nitrobenzoboroxole (400 mg, 2.23 mmol) was stirred in methanol (15 mL) 
under sonication until a white turbid solution was obtained. The solution was cooled to 0 
°C and conc. HCl (2.5 mL) was added. After stirring the reaction mixture for 20 min, 
Zinc powder (1.62 g, 25.0 mmol) was added in three portions at 0 – 5 °C. The reaction 
mixture was stirred overnight at room temperature and was filtered through a celite pad. 
The filtrate was concentrated in vacuo, and the crude mixture was stirred in ethyl acetate 
(20 mL) for 10 min to dissolve the bright red residue. The resulting solution was 
neutralized with 1 M aq. K2CO3 and extracted with ethyl acetate (2 X 10 mL). The 
combined organic extract was washed with brine (1 X 10 mL), dried over Na2SO4, and 
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concentrated under vacuum to furnish pure 6-aminobenzoboroxole as a pale yellow 
powder (260 mg, 78%). The spectral information matched very well with literature data. 
Procedure for the Reductive Amination of Aldehydes 
 To a stirred solution of 6-aminobenzoboroxole (1.34 mmol) in 5 mL of methanol 
was added aryl aldehyde (1.34 mmol) at room temperature and stirred for 2 hours.  Upon 
complete consumption of the reactants (TLC), sodium borohydride (2.01 mmol) was 
added in portions and stirred for 2 hours. After completion of the reaction as indicated by 
TLC, methanol was removed in vacuo and the residue was dissolved in water (5 mL). 
The solution was neutralized to pH 7 with 10% HCl to effect precipitation. The resulting 
solid was filtered, washed with water, and dried under vaccum to afford 6-N-
benzylaminobenzoboroxoles in good yields. This procedure was utilized for the 
preparation of secondary amines 35a-m. 
 
 
  6-(Benzylamino)benzo[c][1,2]oxaborol-1(3H)-ol:Pale cream solid; yield: 82%; mp 123 
– 125 °C; 1H – NMR (400 MHz, DMSO – d6): δ 8.89 (s, 1H), 7.33 (d, J = 7.6 Hz, 2H), 
7.28 (t, J = 7.2 Hz, 2H), 7.18 (d, J = 7.2 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.84 (s, 1H), 
6.73 (d, J = 8.4 Hz, 1H), 6.20 (brs, 1H), 4.79 (s, 2H), 4.26 (s, 2H); 13C – NMR (100 
MHz, DMSO – d6): δ  148.5, 142.2, 141.0, 129.0, 127.8, 127.2, 122.1, 117.2, 113.0, 70.2, 




  6-((4-Fluorobenzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol:Pale cream solid; yield: 
79%; mp 136 – 138 °C; 1H – NMR (400 MHz, DMSO – d6): δ 8.89 (s, 1H), 7.36 (t, J = 
8.8Hz, 2H), 7.11 (t, J = 8.8 Hz, 2H), 7.05 (d, J = 8.0 Hz, 1H), 6.84 (s, 1 H), 6.73 (d, J = 
8.8 Hz, 1H), 6.21 (t, J = 8.8 Hz 1H) 4.80 (s, 2H), 4.24 (d J = 5.2 Hz, 2H); 13C – NMR 
(100  MHz, DMSO – d6): δ 161.7 (d, J = 241.7 Hz), 148.2, 142.3, 137.1 (d, J = 2.8 Hz), 
129.6 (d, J = 8.0 Hz), 122.1, 117,2, 115.6 (d, J = 21.2 Hz), 112.9, 70.2, 46.6; IR (neat): 
3413, 3245, 1508, 1372, 1216, 989, 821, 753 cm-1; ESI – MS: m/z, 272 [M+CH3]+. 
 
 6-((2,4-Difluorobenzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol:Yellow solid; yield: 81%; 
mp 135 – 137 °C; 1H-NMR (400 MHz, DMSO – d6): δ 8.90 (s, 1H), 7.37 (m, 1H), 7.19 
(m, 1H), 7.06 (d, J = 8.0 Hz, 1H), 7.00 (m, 1H), 6.83 (s, 1H), 6.74 (d, J = 7.6 Hz, 1H), 
6.16 (brs, 1H), 4.80 (s, 2H), 4.25 (d, J = 5.2 Hz, 1H); 13C – NMR (100  MHz, DMSO – 
d6): δ 161.9 (dd, J = 244.6, 12.4 Hz), 160.9 (dd, J = 246.6, 12.3 Hz), 148.0, 142.6, 130.9 
(dd, J = 9.5, 6.4 Hz), 123.8 (dd, J = 15.3, 3.5 Hz), 122.3, 117.2, 112.8, 111.9 (dd, J = 
20.9, 2.9 Hz), 104.3 (t, J = 25.8 Hz), 70.2, 46.0; IR (neat): 3398, 3265, 1523, 1235, 1012, 










 6-((2,4-Dichlorobenzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol:Pale cream solid; yield: 
80%; mp 106 – 108 °C;   1H – NMR (400 MHz, DMSO – d6): δ 8.91 (s, 1H), 7.60 (s, 1H), 
7.37 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.75 (s, 1H), 
6.73 (d, J = 8.4 Hz, 1H), 6.32 (t, J = 6.0 Hz, 1H), 4.80 (s, 2H), 4.30 (d, J = 6.0 Hz, 2H); 
13C – NMR (100 MHz, DMSO – d6): δ 147.8, 142.7, 137.0, 133.7, 132.6, 130.5, 129.3, 
128.0, 122.4, 117.3, 112.6, 70.2, 44.8; IR (neat): 3412, 3295, 1286, 1320, 989, 815, 760 
cm-1; ESI – MS: m/z, 322 [M+CH3]+. 
 
 6-((3,4-Dichlorobenzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol: Cream solid; yield: 
78%; mp 128 – 130 °C;   1H – NMR (400 MHz, DMSO – d6): δ 8.90 (s, 1H), 7.57 (s, 1H), 
7.55 ( d, J = 8.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.06 ( d, J = 7.6 Hz, 1H), 6.81 (s, 1H), 
6.72 ( d, J = 8.0 Hz, 1H), 6.32 (t, J = 5.6 Hz, 1H), 4.79 (s, 2H), 4.27 ( d, J = 5.2 Hz, 2H); 
13C – NMR (100 MHz, DMSO – d6): δ  147.9, 142.7, 142.6, 131.6, 131.1, 129.6, 129.5, 
128.1, 122.3, 117.3, 113.1, 70.2, 46.2; IR (neat): 3412, 3289, 1489, 1121, 975, 826, 720 









 6-((4-methoxybenzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol:Pale yellow solid; yield: 
76%; mp 130 – 132 °C; 1H – NMR (400 MHz, DMSO – d6): δ 8.88 (s, 1H), 7.25 (d, J = 
8.8 Hz, 2H), 7.04 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 
6.83 (s, 1H), 6.72 (dd, J = 2.4, 8.4  Hz, 1H), 6.11 (t, J = 6.0 Hz, 1H), 4.78 (s, 2H), 4.17 
(d, J = 6.0 Hz, 2H), 3.69 (s, 3H); 13C – NMR (100 MHz, DMSO – d6): δ 158.7, 148.5, 
142.1, 132.7, 129.0, 122.1, 117.3, 114.4, 113.0, 70.2, 55.7, 46.8; IR (neat): 3298, 2983, 
1526, 1437, 1238, 1172, 769 cm-1; ESI – MS: m/z, 283 [M-H+CH3]+. 
 
 
 4-(((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)amino)methyl)benzoic acid: Pale 
yellow solid; yield: 85%; mp 221 – 223 °C;  1H – NMR (400 MHz, DMSO – d6): δ 12.78 
(s, 1H), 8.89 (s, 1H), 7.87 (d, J = 6.4 Hz, 2H), 7.44 (d, J = 6.4 Hz, 2H), 7.05 (d, J = 8.0 
Hz, 1H), 6.81 (s, 1H), 6.72 (d, J = 8.4 Hz, 2H), 6.36 (bs, 1H), 4.79 (s, 2H), 4.34 (s, 2H); 
13C – NMR (100 MHz, DMSO – d6): δ 167.9, 148.2, 146.6, 142.4, 130.1, 129.8, 127.7, 
122.2, 117.3, 113.0, 70.2, 47.2; IR (neat): 3412, 3278, 1682, 1483, 1289, 984, 817, 753 




solid; yield: 77%; mp 136 – 138 °C; 1H – NMR (400 MHz, DMSO – d6): δ 8.89 (s, 1H), 
7.04 (d, J = 8.8 Hz, 1H), 6.88 (s, 1H), 6.82 (m, 3H), 6.72 (d, J = 8.0 Hz, 1H), 6.14 (t, J = 
5.6 Hz, 1H), 5.94 (s, 2H), 4.75 (s, 2H), 4.15 (d, J = 5.6 Hz, 2H); 13C – NMR (100 MHz, 
DMSO – d6): δ 148.3, 148.0, 146.5, 142.3, 135.0, 122.1, 120.8, 117.3, 113.1, 108.7, 
108.3, 101.4,70.2, 47.1; IR (neat): 3413, 3289. 1525, 1316, 1256, 974, 774 cm-1; ESI – 
MS: m/z, 298 [M+CH3]+. 
 
 4-(((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-
yl)amino)methyl)benzonitrile:Cream solid; yield: 82%; mp 141 – 143 °C; 1H – NMR 
(400 MHz, DMSO – d6): δ 8.89 (s, 1H), 7.76 (d, J = 6.0 Hz, 2H), 7.51 (d, J = 8.4 Hz, 
2H), 7.05 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 1.6 Hz, 1H), 6.72 (d, J = 2.4 Hz, 1H), 6.70 (d, 
J = 2.4 Hz, 1H), 6.37 (t, J = 8.88 Hz 1H), 4.79 (s, 2H), 4.36 (d, J = 6.0 Hz, 2H); 13C – 
NMR (100 MHz, DMSO – d6): δ 148.0, 147.5, 142.6, 132.9, 128.6, 122.3, 119.7, 117.2, 
113.0, 110.0, 70.2, 47.0; IR (neat): 3398, 3265, 2224, 1587, 1387, 974, 819, 725 cm-1; 
ESI – MS: m/z, 279 [M+CH3]+. 
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 6-((4-(Dimethylamino)benzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol: Pale cream solid; 
yield: 74%; mp 122 – 124 °C;  1H – NMR (400 MHz, DMSO – d6): δ 8.90 (s, 1H), 7.16 
(d, J = 7.6 Hz, 2H), 7.05 (d, J = 8.4 Hz, 1H), 6.86 (s, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.67 
(d, J = 7.6 Hz, 2H), 6.01 (t, J = 5.6 Hz, 1H), 4.80 (s, 2H), 4.13 (d, J = 5.6 Hz, 2H), 3.34 
(s, 6H); 13C – NMR (100 MHz, DMSO – d6): δ 150.2, 148.6, 142.0, 128.7, 128.2, 122.0, 
117.3, 113.2, 113.0, 70.3, 47.0; IR (neat): 3357, 3258, 1612, 1443, 1316, 1042, 915, 821, 
726 cm-1; ESI – MS: m/z, 298 [M-H+CH3]+. 
 
 6-((4-(Piperidin-1-yl)benzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol: Orange solid; yield: 
73%; mp 65 – 67 °C;   1H – NMR (400 MHz, DMSO – d6): δ 8.88 (s, 1H), 7.15 (d, J = 8.8 
Hz, 3H), 6.85 (q, 4H), 4.78 (s, 2H), 4.12 ( t, 3H), 3.30 (m, 4H), 3.04 (m, 6H); 13C – NMR 
(100 MHz, DMSO – d6): δ  151.3, 148.6, 142.0, 130.7, 128.6, 122.6, 117.3, 116.6, 112.9 
70.2, 50.5, 46.9, 26.0, 24.6; IR (neat): 3413, 3278, 2930, 1512, 1231, 1129, 808, 724 cm-
1; ESI – MS: m/z, 336 [M-H+CH3]+. 
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 6-((4-(Dibutylamino)benzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol: Pale yellow solid; 
yield: 78%; mp 94 – 96 °C; 1H – NMR (400 MHz, DMSO – d6): δ 8.88 (s, 1H), 7.10 (d, J 
= 8.0 Hz, 2H), 7.03 (d, J = 8.8 Hz, 1H), 6.86 (s, 1H), 6.73 (d, J = 8.8 Hz, 1H), 6.54 (d, J 
= 8.0 Hz, 2H), 5.93 (t, J = 5.4 Hz, 1H), 4.79 (s, 2H), 4.06 (d, J = 5.6 Hz, 2H), 3.19 (t, J = 
7.0 Hz, 4H), 1.43 (m, 4H), 1.27 (m, 4H), 0.87 (m, 6H); 13C – NMR (100 MHz, DMSO – 
d6): δ 148.7, 147.4, 141.9, 129.1, 126.7, 122.0, 117.2, 112.9, 112.1, 70.3, 50.7, 47.0, 29.7, 
20.4, 14.6; IR (neat): 3429, 3298, 2928, 2895, 1517, 1298, 1187, 988, 768 cm-1; ESI – 
MS: m/z, 381 [M+CH3]+. 
 
  6-((4-methylbenzyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol: Pale yellow solid; yield: 
71%; mp 148-150 °C; 1H – NMR (400 MHz, DMSO – d6): δ 8.87 (s, 1H), 7.20 (d, J = 7.6 
Hz, 2H), 7.07 (d, J = 7.6 Hz, 2H), 7.02 (d, J = 8.2 Hz, 1H), 6.81 (s, 1H), 6.71 (d, J = 7.5 
Hz, 1H), 6.14 (br s, 1H), 4.77 (s, 2H), 4.19 (d, J = 5.5 Hz, 2H), 2.22 (s, 3H); 13C – NMR 
(100 MHz, DMSO – d6): δ 148.40, 142.1, 137.8, 136.2, 129.5, 127.7, 125.2, 122.1, 117.2, 
112.9, 70.2, 47.1, 21.3. IR (neat): 3431, 3289, 2926, 2898, 1521, 1194, 982, 771 cm-1; 
ESI – MS: m/z, 267 [M-H+CH3]+. 
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Procedure for the Preparation of Aldehyde 38  
 POCl3 (136 mL, 1.46 mmol) was added to a solution of 4-formylbenzoic acid 37 
(200 mg, 1.33 mmol) and 4-nitro-3-(trifluoromethyl) aniline 36 (247 mg, 1.20 mmol) in 
pyridine (5 mL) at -10 °C dropwise and the reaction was stirred 1 h at the same 
temperature. Upon completion (TLC), the reaction was quenched with cold water and 
extracted with ethyl acetate (2 X 10 mL). The combined organic extracts were washed 
with sat. aq. NaHCO3 solution (1 X 10 mL), brine (1 X 10 mL), and dried over anhydrous 
Na2SO4. The ethyl acetate was concentrated in vacuo and the crude product was purified 
by silica gel column chromatography (ethyl acetate/hexane, 2:8) to yield aldehyde (292 
mg, 72%) as pale yellow solid. M.P 185 – 187 °C; 
 1H – NMR (400 MHz, DMSO – d6): δ 11.12 (s, 1H), 10.10 (s, 1H), 8.43 (s, 1H), 8.31 (d, 
J = 8.8 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.14 (d, J = 8.4 Hz, 2H), 8.05 (d, J = 8.4 Hz, 
2H); 13C – NMR (100 MHz, DMSO – d6): δ 193.5, 166.2, 155.0, 144.3, 142.5, 139.2, 
139.1, 130.3, 130.2, 129.3, 128.2, 124.1, 119.2; IR (neat): 3483, 3370, 2956, 1720, 1680, 






(trifluoromethyl)phenyl)benzamide: Yellow solid; yield: 72%; mp 117 – 119 °C;   1H – 
NMR (400 MHz, DMSO – d6): δ 10.91 (s, 1H), 8.89 (s, 1H), 8.44 (s, 1H), 8.29 (d, J = 8.8 
Hz, 2H), 8.22 (d, J = 8.8 Hz, 2H), 7.92 (d, J = 6.8 Hz, 2H), 7.51 (d, J = 6.8 Hz, 2H), 7.52 
(d, J = 7.6 Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 6.83 (s, 1H), 6.74 (d, J = 8.4 Hz, 2H), 6.36 
(s, 1H), 4.79 (s, 2H), 4.37 (d, J = 5.6 Hz, 2H); 13C – NMR (100 MHz, DMSO – d6): δ 
167.0, 148.2, 146.2, 144.8, 142.4, 132.8, 128.7, 128.3, 127.7, 123.8, 122.2, 119.0, 117.3, 
113.1, 70.2, 47.1; IR (neat): 3418, 3279, 1689, 1539, 1289, 1089, 859, 728 cm-1; ESI – 














 6-(((2-Chloroquinolin-3-yl)methyl)amino)benzo[c][1,2]oxaborol-1(3H)-ol: Yellow solid; 
yield: 81%; mp 209 – 211 °C; 1H – NMR (400 MHz, DMSO – d6): δ 8.87 (s, 1H), 8.24 
(s, 1H), 7.95( d, J = 6.8 Hz, 1H), 7.75 (t, J = 6.8 Hz, 1H), 7.59 (t, J = 7.6 Hz 1H), 7.10 (d, 
J = 7.6 Hz, 1H), 6.81 (d, J = 8.0 Hz, 2H), 6.41 (s, 1H), 4.80 (s, 2H), 4.45 (d, J = 8.0 Hz, 
2H); 13C – NMR (100 MHz, DMSO – d6): δ 150.3, 148.0, 146.8, 142.9, 137.2, 132.0, 
131.0, 128.5, 128.2, 128.0, 127.8, 122.4, 117.5, 112.8, 70.2, 45.5; IR (neat): 3398, 3218, 
2928, 1523, 1140, 978, 756 cm-1; ESI – MS: m/z, 338 [M-H+CH3]+. 
Procedure for the Preparation of N-Nitrosoaminobenzoboroxoles  
 6-N-benzylaminobenzoboroxole (0.37 mmol) was dissolved in a 1:2 mixture of 
acetonitrile and water (3 mL) and the reaction mixture was cooled to 0 °C. HCl (1.86 
mmol) was added dropwise and the mixture was stirred for 30 min at 0 °C. NaNO2 (0.2 
mL, 2 M solution, 0.4 mmol) was added drop wise and the reaction was stirred for 1.5 h, 
during this time, N-nitrosoamine gradually started precipitating out as a pale yellow solid. 
After completion of the reaction (TLC), the solid was filtered, washed with distilled 
water, and dried under vaccu to obtain 6-N-nitroso-N-(benzyl)amino-benzoboroxoles in 






 N-benzyl-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)nitrous amide: Yellow 
solid; yield: 85%; mp 108 – 110 °C; 1H – NMR (400 MHz, DMSO – d6): δ 9.29 (s, 1H), 
7.89 (s, 1H), 7.73 (m, 1H), 7.52 (m, 1H), 7.21 – 7.28 (m, 3H), 7.05 (m, 2H), 5.33 (s, 2H), 
5.00 (s, 2H); 13C – NMR (100 MHz, DMSO – d6): δ 153.7, 140.9, 135.2, 129.4, 128.0, 
127.7, 123.5, 123.3, 122.5, 70.5, 47.4; IR (neat): 2923, 1437, 1369, 1120, 977, 937, 749 
cm-1; ESI – MS: m/z, 282 [M-H+CH3]+. 
 
 
  N-(4-fluorobenzyl)-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)nitrous 
amide:Yellow solid; yield: 86%; mp 121 – 123 °C; 1H – NMR (400 MHz, DMSO – d6): δ 
9.31 (s, 1H), 7.88 (s, 1H), 7.73 (d, J = 6.4 Hz, 1H), 7.53 (d, J =  8.0 Hz, 1H), 7.10 (d, J =  
6.8 Hz, 4H), 5.32 (s, 1H), 5.01 (s, 1H); 13C – NMR (100 MHz, DMSO – d6): δ 162.0 (d, J 
= 243.6 Hz), 153.8, 140.7, 131.4 (d, J = 3.1 Hz), 129.9 (d, J = 8.3 Hz), 123.7, 123.4, 
122.6, 116.2 (d, J = 21.6 Hz), 70.5, 46.8; IR (neat): 2985, 1454, 1384, 1217, 1120, 978, 




amide:Brownish solid; yield: 88%; mp 125 – 127 °C;   1H – NMR (400 MHz, DMSO – 
d6): δ  9.31 (s, 1H), 7.87 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.20 
(m, 1H), 7.10 (m, 1H), 6.98 (m, 1H), 5.31 (s, 2H), 5.01 (s, 2H); 13C – NMR (100 MHz, 
DMSO – d6): 13C NMR (100 MHz, DMSO –d6): δ 162.36 (dd, J = 246.8, 12.6 Hz), 
160.62 (dd, J = 248.9, 12.8 Hz), 154.0, 140.4, 131.56 (dd, J = 10.0, 5.4 Hz), 124.2, 123.3, 
123.2, 118.37 (dd, J = 15.0, 3.7 Hz), 112.37 (d, J = 21.5 Hz), 104.80 (t, J = 25.9 














amide:Brownish solid; yield: 88%; mp 121 – 123 °C; 1H – NMR (400 MHz, DMSO – 
d6): δ 9.31 (s, 1H), 7.85 (d, J = 1.6 Hz, 1H), 7.72 (dd, J = 8.0 Hz, 1H), 7.62 (d, J = 2.0 
Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.33 (dd, J = 8.0 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 
5.32 (s, 2H), 5.01 (s, 2H); 13C – NMR (100 MHz, DMSO – d6): δ 154.0, 140.4, 133.7, 
133.6, 131.4, 130.9, 129.8, 128.3, 124.0, 123.3 122.9, 70.5, 45.6; IR (neat): 2927, 1438, 
1133, 977, 830 cm-1; ESI – MS: m/z, 350 [M-H+CH3]+. 
 
N-(3,4-dichlorobenzyl)-N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)nitrous 
amide:Yellow solid; yield: 87%; mp 144 – 147 °C; 1H – NMR (400 MHz, DMSO – d6): δ 
9.30 (s, 1H), 7.88 (s, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.38 (s, 1H), 
6.99 (d, J = 8.4 Hz, 1H), 5.33 (s, 2H), 5.02 (s, 2H); 13C – NMR (100 MHz, DMSO – d6): 
δ 153.9, 140.6, 136.3, 131.9, 131.6, 130.8, 129.9, 127.9, 123.6, 123.4, 122.5, 70.5, 46.6; 





amide:Yellow solid;  yield: 83%; mp 110 – 112 °C; 1H – NMR (400 MHz, DMSO – d6): 
δ 9.30 (s, 1H), 7.87 (d, J = 1.6 Hz, 1H), 7.72 (dd, J = 2.0, 8.4 Hz, 1H), 7.52 (d, J = 8.4 Hz, 
1H), 6.99 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 5.26 (s, 2H), 5.00 (s, 2H), 3.67 (s, 
3H); 13C – NMR (100 MHz, DMSO – d6): δ 159.2, 153.7, 140.8, 129.3, 127.0, 123.7, 
123.3, 122.7, 114.8, 70.4, 55.7, 46.7; IR (neat): 2928, 1453, 1404, 1179, 1124, 787 cm-1; 
ESI – MS: m/z, 312 [M-H+CH3]+. 
Procedure for the Synthesis of N-Benzoboroxolyl Ureas  
 2-Chloroethyl isocyanate (0.37 mmol) was added to the solution of 6-N-
(benzyl)aminobenzoboroxole (0.37 mmol) in dioxane (3 mL) and the reactionwas stirred 
overnight at room temperature. After completion of the reaction (TLC), the solvent was 
removed in vacuo and the residue was diluted with deionized water. The resulting solid 
was filtered, washed with water, and dried under vaccum. The crude solid was triturated 









cream solid; yield: 82%; mp 116 – 118 °C; 1H – NMR (400 MHz, DMSO – d6): δ  9.16 
(s, 1H), 8.00 (s, 1H),7.54 (s, 1H), 7.16 – 7.40 (m, 10H), 6.91 (t, J = 8.4 Hz, 2H), 4.94 (s, 
2H), 4.90 (s, 2H); 13C – NMR (100 MHz, DMSO – d6): δ 155.6, 152.5, 141.7, 140.7, 
139.3, 130.6, 129.9, 129.5, 129.0, 128.9, 128.2, 127.6, 123.1, 122.8, 120.6, 118.9, 70.5, 












phenylurea:Pale brown solid; yield: 84%; mp 104 – 106 °C; 1H – NMR (400 MHz, 
DMSO – d6): δ 9.17 (s, 1H), 7.94 (s, 1H), 7.51 (s, 1H), 7.38 (m, 3H), 7.26 (d, J = 8.4 Hz, 
1H), 7.12-7.21 (m, 4H), 6.92 (t, J = 7.17 Hz, 1H), 6.82 (d, J = 8.4 Hz, 2H), 4.82 (s, 2H), 
4.98 (s, 2H), 3.68 (s, 3H); 13C – NMR (100 MHz, DMSO – d6): δ 159.0, 155.6, 152.5, 
141.6, 140.7, 131.1, 130.7, 130.0, 129.6, 129.5, 128.9, 123.1, 122.7, 120.6, 114.4, 70.5, 
67.0, 55.6, 52.9; IR (neat): 2928, 1640, 1512, 1405, 1241, 1208, 974, 747 cm-1; ESI – 









 1-Benzyl-3-cyclohexyl-1-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)urea: Pale 
cream solid; yield: 80%; mp 125 – 127 °C; 1H – NMR (400 MHz, DMSO – d6): δ 9.18 
(s,1H), 7.48 (s,1H), 7.35 (d, J = 7.6 Hz, 2H), 7.18 – 7.29 (m, 5H), 5.34 (d, J = 8.0 Hz, 
1H), 4.94 (s, 2H), 4.82 (s, 2H), 3.48 (m, 1H), 1.50 – 1.71 (m, 4H), 0.97 – 1.24 (m, 6H); 
13C – NMR (100 MHz, DMSO – d6): δ 156.9, 152.3, 141.9, 139.8, 130.8, 130.0, 128.9, 
128.1, 127.4, 123.1, 70.4, 53.1, 50.0, 33.4, 25.6; IR (neat): 3295, 1654, 1434, 1289, 1021, 












methoxybenzyl) urea: Off white solid; yield: 81%; mp 156 – 158 °C; 1H – NMR (400 
MHz, DMSO – d6): δ 9.16 (s, 1H), 7.42 (s, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 8.4 
Hz, 1H), 7.07 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 8.0 Hz, 2H), 5.23 (d, J = 8.4 Hz, 1H), 4.92 
(s, 2H), 4.71 (s, 2H), 3.67 (s, 3H), 3.44 (m, 1H), 1.48 – 1.68 (m, 4H), 0.97 – 1.24 (m, 
6H); 13C – NMR (100 MHz, DMSO – d6): δ 158.8, 156.8, 152.3, 141.8, 131.6, 130.9, 
130.2, 129.5, 123.0, 114.3, 55.6, 49.9, 34.0, 33.4, 25.8, 25.5; IR (neat): 2923, 1623, 1513, 













yl)urea:Pale cream solid; yield: 79%; mp 138 – 140 °C; 1H – NMR (400 MHz, DMSO – 
d6): δ 9.18 ( s,1H), 7.46 (s,1H), 7.36 (d, J = 8.4 Hz,1H), 7.16 – 7.27 (m, 6H), 6.00 (t, J = 
5.6 Hz, 1H), 4.93 (s, 2H), 4.79 (s, 2H), 3.54 (t, J = 6.4 Hz, 2H), 3.31 (m, 2H); 13C – NMR 
(100 MHz, DMSO – d6): δ 157.5, 152.9, 141.3, 139.5, 131.2, 130.6, 128.9, 128.2, 127.5, 
123.3, 70.5, 53.3, 44.1, 42.9; IR (neat): 3214, 2913, 1635, 1554, 1323, 1158, 876, 715 















methoxybenzyl) urea: Colorless solid; yield: 82%; mp 125 – 127 °C; 1H – NMR (400 
MHz, DMSO – d6): δ 9.18 (s, 1H), 7.42 (s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 7.17 (dd, J = 
1.6, 8.4 Hz, 1H), 7.07 (d, J = 8.0 Hz, 2H), 6.80 (d, J = 8.8 Hz, 2H), 5.92 (t, J = 5.6 Hz, 
1H), 4.93 (s, 2H), 4.71 (s, 2H), 3.68 (s, 3H), 3.53 (t, J = 6.4 Hz, 2H), 3.28-3.30 (m, 2H); 
13C – NMR (100 MHz, DMSO – d6): δ 158.8, 157.4, 152.9, 141.2, 131.4, 130.7(2C), 
129.6 (2C), 123.2, 114.3 (2C), 70.5, 55.6, 52.6, 44.1, 42.9; IR (neat): 3244, 2932, 1640, 









Cell Viability Assay  
 Human pancreatic cancer MIAPaCa-2 cells were purchased from ATCC and were 
maintained in D-MEM supplemented with 10% FBS, 2.5% horse serum, and 1% 
Penicillin Streptomycin in a humidified atmosphere of 5% CO2 at 37 °C. Human breast 
cancer MDA-MB-231 cells were purchased from ATCC and were maintained in D-MEM 
supplemented with 10% FBS and 1% Penicillin Streptomycin in a humidified atmosphere 
of 5% CO2 at 37 °C. Cells were seeded in 96 well plates at a density of 5 X 104 
cells/mL, incubated for 18e24 h, then exposed to benzoboroxoles 1-21 at 50 mM and 
12.5 mM concentrations in duplicate for 72 h. DMSO was added as a negative control. 
To determine the cell viability, MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) was dissolved in PBS solution (5 mg/mL) and 10 mL was 
added to each well and incubated. After 4 h, 100 mL of SDS (sodium dodecyl sulfate) 
solution (1 g in 10 mL of 0.01 N HCl) was added to solubilize formazan precipitate and 
incubated for an additional 4 h. The absorbance of each well was then measured using a 
microplate reader at 570 nm. The absorbance of control wells was defined as 100% 
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